Glucocorticoids are standard of care for a host of allergic and inflammatory eye conditions, but they elevate intraocular pressure about a third of the time and can result in secondary open-angle glaucoma. A chemical chaperone called sodium phenylbutyrate could eliminate that side effect, according to new research from The University of Iowa.1
The findings may hand a new indication to two companies-one Swedish, one Canadian-that market oral versions of phenylbutyrate (PBA) for other diseases.
Glaucomas develop when aqueous fluid that enters the eye via the ciliary body is not effectively drained through structures including the trabecular meshwork. This leads to elevated intraocular pressure (IOP) and causes progressive degeneration of retinal ganglion cells and damage to the optic nerve. The ultimate result is visual